Clinical Trial Update: Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) [Phase 3]

View source ↗

Summary

Phase 3 trial in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: Pfizer | Conditions: Diffuse Large B-Cell Lymphoma | Phase 3 | Status: TERMINATED | Results posted: 2020-12-17